Skip to main content
abstract
January 07, 2026

Strengthening Life Sciences IP Before Going Clinical

By Heidi Erlacher, Matthew Pavao
Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.
abstract
January 07, 2026

Strengthening Life Sciences IP Before Going Clinical

By Heidi Erlacher, Matthew Pavao
Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.
Abstact
December 22, 2025

Regulatory Considerations in Connection with Clinical Data Release

By Chelsea Anderson,Rob Freedman,Ryan Mitteness,Amanda Rose +1more...
Show Less
Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets.
Abstact
December 22, 2025

Regulatory Considerations in Connection with Clinical Data Release

By Chelsea Anderson,Rob Freedman,Ryan Mitteness,Amanda Rose +1 more...
Show Less
Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets.
Data
December 18, 2025

Preparing for Clinical Data Release

By Chelsea Anderson,Rob Freedman,Ryan Mitteness,Amanda Rose +1more...
Show Less
For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.
Data
December 18, 2025

Preparing for Clinical Data Release

By Chelsea Anderson,Rob Freedman,Ryan Mitteness,Amanda Rose +1 more...
Show Less
For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.
Healthcare startup
December 17, 2025

The Real Test of a Founder Isn’t the ‘What,’ It’s the ‘Why’

By Michael Esquivel
In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.
Healthcare startup
December 17, 2025

The Real Test of a Founder Isn’t the ‘What,’ It’s the ‘Why’

By Michael Esquivel
In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.
Financial chart
December 16, 2025

Q3 2025 Contains Multitudes: Secondary Market and Convertible Financing Trends

By Allison Cooper, Katherine Duncan, Mark A. Leahy
The venture market in Q3 2025 resists simple characterization. Secondary market transaction volume remained muted, yet premium pricing rose to 38% of deals.
Financial chart
December 16, 2025

Q3 2025 Contains Multitudes: Secondary Market and Convertible Financing Trends

By Allison Cooper, Katherine Duncan, Mark A. Leahy
The venture market in Q3 2025 resists simple characterization. Secondary market transaction volume remained muted, yet premium pricing rose to 38% of deals.
From Breakthroughs to Backing – What Life Sciences Investors Want
December 15, 2025

Video: From Breakthroughs to Backing – What Life Sciences Investors Want

By Chelsea Anderson, Rob Freedman, Amanda Rose
Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.
From Breakthroughs to Backing – What Life Sciences Investors Want
December 15, 2025

Video: From Breakthroughs to Backing – What Life Sciences Investors Want

By Chelsea Anderson, Rob Freedman, Amanda Rose
Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.
biotechnology
December 09, 2025

Congress Advances BIOSECURE Act: What Federal Contractors Can Do to Prepare

By Melissa Duffy,Robert Slack,Jerzy Piatkowski,Carrie Schroll +1more...
Show Less
Congress is inching closer to passing the BIOSECURE Act and imposing restrictions on federal agencies and grant recipients related to biotechnology companies of concern.
biotechnology
December 09, 2025

Congress Advances BIOSECURE Act: What Federal Contractors Can Do to Prepare

By Melissa Duffy,Robert Slack,Jerzy Piatkowski,Carrie Schroll +1 more...
Show Less
Congress is inching closer to passing the BIOSECURE Act and imposing restrictions on federal agencies and grant recipients related to biotechnology companies of concern.
A microchip on a circuit board, representing AI.
December 09, 2025

AI Startups Keep Their Market Edge in Q3 2025, But Sustainability Questions Linger

By Allison Cooper, Katherine Duncan, Mark A. Leahy
Q3 2025 confirmed what many venture observers suspected: Startups deploying or developing AI technologies continue to command higher valuations than their non-AI peers.
A microchip on a circuit board, representing AI.
December 09, 2025

AI Startups Keep Their Market Edge in Q3 2025, But Sustainability Questions Linger

By Allison Cooper, Katherine Duncan, Mark A. Leahy
Q3 2025 confirmed what many venture observers suspected: Startups deploying or developing AI technologies continue to command higher valuations than their non-AI peers.
Table and chairs in a modern meeting space.
December 03, 2025

2025 Proxy Results: Company‑Sponsored Governance Reforms Passed Easily; Proposal Volumes Shifted Across Categories

By Wendy Grasso, David Bell

Company proposals continued to pass at high rates, especially governance‑focused items.

Table and chairs in a modern meeting space.
December 03, 2025

2025 Proxy Results: Company‑Sponsored Governance Reforms Passed Easily; Proposal Volumes Shifted Across Categories

By Wendy Grasso, David Bell

Company proposals continued to pass at high rates, especially governance‑focused items.